Wealth Enhancement Advisory Services LLC Decreases Stock Holdings in CRISPR Therapeutics AG $CRSP

Key Points

• Wealth Enhancement Advisory Services LLC decreased its holdings in CRISPR Therapeutics by 12.2%, selling 11,493 shares during the second quarter, leaving them with approximately 82,607 shares valued at $4.31 million.
• Several analysts have recently issued ratings on CRISPR Therapeutics, with a current consensus rating of "Moderate Buy" and an average price target set at $71.50.
• Director Simeon George significantly increased his stake by acquiring 989,812 shares at $52.03 each, raising his total ownership to approximately $90 million.

Wealth Enhancement Advisory Services LLC reduced its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 12.2% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 82,607 shares of the company's stock after selling 11,493 shares during the quarter. Wealth Enhancement Advisory Services LLC owned approximately 0.10% of CRISPR Therapeutics worth $4,310,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. SVB Wealth LLC purchased a new position in shares of CRISPR Therapeutics in the 1st quarter worth about $25,000. Wood Tarver Financial Group LLC bought a new stake in CRISPR Therapeutics in the fourth quarter worth about $30,000. Costello Asset Management INC purchased a new position in CRISPR Therapeutics in the first quarter valued at about $27,000. Ameriflex Group Inc. bought a new position in shares of CRISPR Therapeutics during the 4th quarter valued at approximately $36,000. Finally, Quantbot Technologies LP grew its position in shares of CRISPR Therapeutics by 272.4% during the 1st quarter. Quantbot Technologies LP now owns 1,337 shares of the company's stock valued at $45,000 after acquiring an additional 978 shares during the period. Institutional investors own 69.20% of the company's stock.

Analyst Ratings Changes

Several research firms recently commented on CRSP. Bank of America dropped their price objective on CRISPR Therapeutics from $79.00 to $78.00 and set a "buy" rating on the stock in a research note on Tuesday, July 22nd. JPMorgan Chase & Co. started coverage on CRISPR Therapeutics in a research report on Thursday, September 18th. They set an "overweight" rating and a $70.00 price target on the stock. Chardan Capital reiterated a "buy" rating and set a $82.00 price target on shares of CRISPR Therapeutics in a research note on Tuesday, August 5th. HC Wainwright restated a "buy" rating and issued a $80.00 price objective on shares of CRISPR Therapeutics in a research note on Tuesday. Finally, Piper Sandler restated an "overweight" rating and issued a $105.00 price objective on shares of CRISPR Therapeutics in a research note on Friday, June 27th. Ten equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $71.50.

Insiders Place Their Bets

In other news, Director Simeon George bought 989,812 shares of the firm's stock in a transaction that occurred on Wednesday, July 16th. The shares were acquired at an average price of $52.03 per share, with a total value of $51,499,918.36. Following the acquisition, the director owned 1,730,179 shares of the company's stock, valued at approximately $90,021,213.37. The trade was a 133.69% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 4.30% of the company's stock.

CRISPR Therapeutics Stock Performance

NASDAQ:CRSP opened at $60.32 on Friday. The business's fifty day moving average is $57.66 and its 200 day moving average is $46.78. The firm has a market cap of $5.49 billion, a price-to-earnings ratio of -11.11 and a beta of 1.81. CRISPR Therapeutics AG has a 52-week low of $30.04 and a 52-week high of $71.13.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last posted its earnings results on Monday, August 4th. The company reported ($1.29) earnings per share for the quarter, beating analysts' consensus estimates of ($1.47) by $0.18. CRISPR Therapeutics had a negative return on equity of 20.05% and a negative net margin of 1,229.43%.The business had revenue of $0.89 million during the quarter, compared to analyst estimates of $6.44 million. During the same quarter in the previous year, the firm earned ($1.49) EPS. The company's quarterly revenue was up 72.5% compared to the same quarter last year. Equities analysts predict that CRISPR Therapeutics AG will post -5.16 EPS for the current fiscal year.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.

Want to see what other hedge funds are holding CRSP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.